Literature DB >> 12766905

Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas.

Maria I Patrikis1, Emma J Bryan, Nicola A Thomas, Greg E Rice, Michael A Quinn, Mark S Baker, Ian G Campbell.   

Abstract

Leiomyomas are the most common gynecologic tumors in women, but very little is known about their molecular pathology. We used single-stranded conformational polymorphism/heteroduplex analysis to analyze 42 unselected uterine leiomyomas for somatic mutations in all coding exons of the gene encoding CCAAT displacement protein (CDP), as well as exons 5-8 of TP53 and codons 1-36 and 38-80 of KRAS. No somatic mutations were identified in either TP53 or KRAS, indicating that disregulation of these genes is not required for leiomyomas development. Aberrant band shifts were identified in CDP, but these were all germline nonpathogenic variants that have been reported previously. There is good functional and genetic evidence indicating that CDP is a leiomyoma suppressor, but our data suggested that somatic mutations in this gene were rare in unselected uterine leiomyomas. It is possible that CDP belongs to a class of tumor suppressor in which loss of only one copy of the gene, either by genetic or epigenetic mechanisms, is sufficient to allow tumor growth. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766905     DOI: 10.1002/mc.10127

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  6 in total

Review 1.  Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.

Authors:  Arno E Commandeur; Aaron K Styer; Jose M Teixeira
Journal:  Hum Reprod Update       Date:  2015-07-03       Impact factor: 15.610

2.  The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).

Authors:  Bartosz Wasag; Els Lierman; Peter Meeus; Jan Cools; Peter Vandenberghe
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

Review 3.  CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers.

Authors:  Zubaidah M Ramdzan; Alain Nepveu
Journal:  Nat Rev Cancer       Date:  2014-09-05       Impact factor: 60.716

4.  RAS transformation requires CUX1-dependent repair of oxidative DNA damage.

Authors:  Zubaidah M Ramdzan; Charles Vadnais; Ranjana Pal; Guillaume Vandal; Chantal Cadieux; Lam Leduy; Sayeh Davoudi; Laura Hulea; Lu Yao; Anthony N Karnezis; Marilène Paquet; David Dankort; Alain Nepveu
Journal:  PLoS Biol       Date:  2014-03-11       Impact factor: 8.029

5.  Association of XRCC1 Arg399GIn and Tp53 Arg72Pro polymorphisms and increased risk of uterine leiomyoma - A case-control study.

Authors:  Minoo Yaghmaei; Saeedeh Salimi; Lida Namazi; Farzaneh Farajian-Mashhadi
Journal:  Genet Mol Biol       Date:  2015-11-24       Impact factor: 1.771

6.  Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations.

Authors:  Eucharist H S Kun; Yvonne T M Tsang; Sophia Lin; Sophia Pan; Tejas Medapalli; Anais Malpica; JoAnne S Richards; David M Gershenson; Kwong-Kwok Wong
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.